Qelbree (viloxazine) and trazodone concomitant use risks
Concomitant use is not listed as a specific contraindication in available prescribing information, but clinically relevant additive adverse-effect risks can occur based on each product’s labeled safety warnings. [1]
Medication interaction profile
No specific Qelbree–trazodone pharmacokinetic interaction is described in the available Qelbree prescribing information. [1] Trazodone prescribing information highlights interaction risks with serotonergic drugs and drugs that impair serotonin metabolism (including MAOIs), with CYP3A4 inhibitors affecting trazodone exposure, and with agents that increase QT interval. [2]
Additive CNS effects
Qelbree can cause somnolence and fatigue and can impair alertness, requiring caution with activities requiring mental alertness. [1] Trazodone can have CNS depressant effects and can increase the response to alcohol, barbiturates, and other CNS depressants. [2] Concomitant use can therefore increase the likelihood of excessive sedation, lethargy, and impaired psychomotor performance based on the labeled CNS effects of both agents. [1], [2]
Serotonin syndrome risk assessment
Trazodone prescribing information warns that serotonin syndrome or NMS-like reactions can occur, particularly with concomitant use of other serotonergic drugs and with drugs that impair metabolism of serotonin, including MAOIs. [2] Qelbree prescribing information does not describe a specific serotonin-syndrome interaction with trazodone in the available label excerpts used for this answer. [1] When trazodone is used concurrently with any additional serotonergic agent, close monitoring for serotonin syndrome is recommended per trazodone labeling. [2]
CYP-mediated interaction considerations
Qelbree is labeled to significantly increase total exposure of sensitive CYP1A2 substrates, increasing adverse-reaction risk for those CYP1A2 substrates. [3] Trazodone labeling emphasizes interactions with CYP3A4 inhibitors and does not identify trazodone as a CYP1A2 substrate in the provided label excerpts. [2] Therefore, the main CYP-based interaction consideration for this specific pair is not established from the provided labeling excerpts, but CYP1A2 drug safety should still be assessed when other medications metabolized by CYP1A2 are present. [1], [2], [3]
Cardiovascular safety monitoring
Qelbree labeling requires assessment of heart rate and blood pressure before initiation, after dosage increases, and periodically during therapy due to labeled increases in heart rate and blood pressure. [4] Trazodone labeling includes QT prolongation and sudden-death risk considerations and advises avoiding use with drugs that increase the QT interval and using caution in patients at risk for prolonged QT interval (including in the setting of relevant drug interactions). [2] Concomitant use warrants attention to cardiovascular adverse effects that could be independently present from each drug’s labeled warnings, including monitoring for hemodynamic changes and QT-risk medications in the overall regimen. [2], [4]
Practical risk-management points from labeling
Excessive sedation should be monitored for, due to Qelbree-labeled somnolence/fatigue and trazodone-labeled CNS-depressant potential. [1], [2] Serotonin syndrome vigilance should be maintained when trazodone is used with other serotonergic agents or MAOIs. [2] Blood pressure and heart rate monitoring should follow Qelbree labeling schedules. [4] QT-prolongation risk should be reviewed for the full medication regimen when trazodone is used, including avoidance of QT-prolonging drugs and attention to drug–drug interaction potential that increases trazodone exposure. [2]
When to escalate evaluation
Emergency evaluation is warranted for symptoms consistent with serotonin syndrome (for example, agitation, confusion, diaphoresis, fever, rigidity, or tremor) or for symptoms consistent with serious cardiac rhythm problems as cautioned in trazodone warnings. [2] Urgent reassessment is warranted for clinically significant blood pressure or heart-rate elevations during Qelbree treatment consistent with labeled monitoring indications. [4]